Heterogeneity of pre-diabetes and type 2 diabetes: Implications for prediction, prevention and treatment responsiveness

Current Diabetes Reviews

Volumn 12, Issue 1, 2016, Pages 30-41

  Færch, Kristine ^a   Hulmán, Adam ^b   Solomon, Thomas P J ^c,d  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d University of Copenhagen   (Denmark)

Author keywords

Beta cell dysfunction; Diabetes management; Diabetes prediction; Diagnostic criteria; Fasting glucose; Insulin resistance; Obesity; Physical activity; Postprandial glucose; Weight loss

Indexed keywords

HEMOGLOBIN A1C; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

BARIATRIC SURGERY; DIET RESTRICTION; EXERCISE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE QUALITY; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; METABOLISM; PREDIABETIC STATE; PROCEDURES; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; PREDIABETIC STATE; WEIGHT LOSS;

EID: 84947752712     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399811666150416122903     Document Type: Review

References (150)

1. Perreault L, Færch K. Approaching Pre-diabetes. J Diabetes Complications 2014; 28(2): 226-33.
2. Færch K, Johansen NB, Vistisen D, et al. Cardiovascular risk stratification and management in pre-diabetes. Curr Diab Rep 2014; 14: 493.
3. World-Health Organization and International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva: World Health Organization; 2006.
4. American Diabetes Association. Standards of Medical Care in Diabetes-2013. Diabetes Care 2014; 37: S14-S80.
5. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Abreviated Report of a WHO Consultation. Geneva, Switzerland; 2011.
6. Færch K, Witte DR, Tabak AG, et al. Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study. Lancet Diabetes & Endocrinology 2013; 1(1): 43-51.
7. Færch K, Borup-Johansen N, Witte DR, et al. Relationship between insulin resistance and beta cell dysfunction in subphenotypes of pre-diabetes and type 2 diabetes. J Clin Endocrinol Metab 2014; 100(2): 707-16.
8. Solomon TJ, Malin SK, Karstoft K, et al. The influence of hyperglycemia on the therapeutic effect of exercise on glycemic control in patients with type 2 diabetes mellitus. JAMA Internal Medicine 2013; 173(19): 1834-6.
9. Solomon TP, Malin SK, Karstoft K, et al. Pancreatic beta-cell function is a stronger predictor of changes in glycemic control after an aerobic exercise intervention than insulin sensitivity. J Clin Endocrinol Metab 2013; 98(10): 4176-86.
10. Sharoff CG, Hagobian TA, Malin SK, et al. Combining short-term metformin treatment and one bout of exercise does not increase insulin action in insulin-resistant individuals. Am J Physiol Endocrinol Metab 2010; 298(4): E815-E823.
11. Ruchat SM, Rankinen T, Weisnagel SJ, et al. Improvements in glucose homeostasis in response to regular exercise are influenced by the PPARG Pro12Ala variant: results from the HERITAGE Family Study. Diabetologia 2010; 53(4): 679-89.
12. Leahy JL. Pathogenesis of Type 2 Diabetes Mellitus. Archives of Medical Research 2005; 36(3): 197-209.
13. Unger RH, Aguilar-Parada E, Müller WA, et al. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 1970; 49(4): 837-48.
14. Dunning BE, Gerich JE. The Role of Alpha-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications. Endocr Rev 2007; 28(3): 253-83.
15. Vilsbøll T, Knop FK, Krarup T, et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 2003; 88(10): 4897-903.
16. Færch K, Torekov SS, Vistisen D, et al. Glucagon-Like Peptide-1 (GLP-1) Response to Oral Glucose is Reduced in Pre-diabetes, Screen-detected Type 2 Diabetes and Obesity, and Influenced by Sex: The ADDITION-PRO Study. Diabetes 2015 Feb 12 [Epub ahead of print].
17. Rasouli N, Kern PA. Adipocytokines and the Metabolic Complications of Obesity. J Clin Endocrinol Metab 2008; 93: S64-S73.
18. Basu A, Basu R, Shah P, et al. Systemic and regional free fatty acid metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 2001; 280(6): E1000-E1006.
19. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37(6): 667-87.
20. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989; 38(4): 387-95.
21. Perreault L, Bergman BC, Playdon MC, et al. Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of prediabetes? Am J Physiol Endocrinol Metab 2008; 295(2): E428-E435.
22. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999; 48(11): 2197-203.
23. Abdul-Ghani MA, Jenkinson CP, Richardson DK, et al. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance-Results from the veterans administration genetic epidemiology study. Diabetes 2006; 55(5): 1430-5.
24. Bock G, Man CD, Campioni M, et al. Pathogenesis of Pre-Diabetes: Mechanisms of Fasting and Postprandial Hyperglycemia in People With Impaired Fasting Glucose and/or Impaired Glucose Tolerance. Diabetes 2006; 55(12): 3536-49.
25. Baron AD, Schaeffer L, Shragg P, et al. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1987; 36(3): 274-83.
26. Kolterman OG, Gray RS, Griffin J, et al. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. J Clin Invest 1981; 68(4): 957-69.
27. Færch K, Vaag A, Holst J, et al. Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia 2008; 51(5): 853-61.
28. Meyer C, Szoke E, Pimenta W, et al. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 2006; 29(8): 1909-14.
29. Tripathy D, Almgren P, Tuomi T, et al. Contribution of insulinstimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care 2004; 27(9): 2204-10.
30. Jani R, Molina M, Matsuda M, et al. Decreased non-insulindependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range. Diabetes Care 2008; 31(2): 311-5.
31. Perreault L, Færch K, Kerege AA, et al. Hepatic glucose sensing is impaired, but can be normalized, in people with impaired fasting glucose. J Clin Endocrinol Metab 2014; 99(7): E1154-62.
32. DeFronzo RA. Banting Lecture. From the Triumvirate to the Ominous Octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58(4): 773-95.
33. Færch K, Vaag A, Holst JJ, et al. Natural History of Insulin Sensitivity and Insulin Secretion in the Progression from Normal Glucose Tolerance to Impaired Fasting Glycemia and Impaired Glucose Tolerance-The Inter99 study. Diabetes Care 2009; 32(3): 439-44.
34. Butler AE, Janson J, Bonner-Weir S, et al. Beta-Cell Deficit and Increased Beta-Cell Apoptosis in Humans With Type 2 Diabetes. Diabetes 2003; 52(1): 102-10.
35. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007; 117(8): 2155-63.
36. Sparsø T, Bonnefond A, Andersson E, et al. G-allele of Intronic rs10830963 in MTNR1B Confers Increased Risk of Impaired Fasting Glycemia and Type 2 Diabetes Through an Impaired Glucose-Stimulated Insulin Release. Diabetes 2009; 58(6): 1450-6.
37. Rose CS, Grarup N, Krarup N, et al. A variant in the G6PC2/ABCB11 locus is associated with fasting plasma glucose, increased basal hepatic glucose production and increased insulin release after oral and intravenous glucose loads. Diabetologia 2009; 52(10): 2122-9.
38. Bouatia-Naji N, Rocheleau G, Van-Lommel L, et al. A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 2008; 320(5879): 1085-8.
39. Preis SR, Massaro JM, Robins SJ, et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity 2010; 18(11): 2191-8.
40. Wander PL, Boyko EJ, Leonetti DL, et al. Change in visceral adiposity independently predicts a greater risk of developing type 2 diabetes over 10 years in Japanese Americans. Diabetes Care 2013; 36(2): 289-93.
41. Assah FK, Brage S, Ekelund U, et al. The association of intensity and overall level of physical activity energy expenditure with a marker of insulin resistance. Diabetologia 2008; 51(8): 1399-407.
42. Balkau B, Mhamdi L, Oppert JM, et al. Physical Activity and Insulin Sensitivity: The RISC Study. Diabetes 2008; 57(10): 2613-8.
43. Færch K, Vaag A, Witte DR, et al. Predictors of future fasting and 2-hour post-OGTT plasma glucose levels in middle-aged men and women-the Inter99 study. Diabetic Med 2009; 26(4): 377-83.
44. Healy GN, Dunstan DW, Shaw JE, et al. Beneficial associations of physical activity with 2-h but not fasting blood glucose in Australian adults. Diabetes Care 2006; 29(12): 2598-604.
45. Feskens EJ, Virtanen SM, Räsänen L, et al. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 1995; 18(8): 1104-12.
46. Van Dam RM, Stampfer M, Willett WC, et al. Dietary fat and meat intake in relation to risk of type 2 diabetes in men. Diabetes Care 2002; 25(3): 417-24.
47. Storlien LH, Kriketos AD, Jenkins AB, et al. Does dietary fat influence insulin action? Ann N Y Acad Sci 1997; 827: 287-301.
48. Florez J. Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: Where are the insulin resistance genes? Diabetologia 2008; 51(7): 1100-10.
49. Kanat M, Mari A, Norton L, et al. Distinct beta-cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes 2012; 61(2): 447-53.
50. Færch K, Borch-Johnsen K, Holst JJ, et al. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia 2009; 52(9): 1714-23.
51. Chang-Chen K, Mullur R, Bernal-Mizrachi E. Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord 2008; 9(4): 329-43.
52. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63(2): 492-8.
53. Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29(1): 46-52.
54. Vaag AA, Holst JJ, Vølund A, et al. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)-evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 1996; 135(4): 425-32.
55. Nauck MA, Vardarli I, Deacon CF, et al. Secretion of glucagonlike peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011; 54(1): 10-8.
56. Calanna S, Christensen M, Holst JJ, et al. Secretion of glucagonlike peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 2013; 56(5): 965-72.
57. Zhang F, Tang X, Cao H, et al. Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance. Int J Med Sci 2012; 9(7): 574-81.
58. Muscelli E, Mari A, Casolaro A, et al. Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients. Diabetes 2008; 57(5): 1340-8.
59. Alssema M, Rijkelijkhuizen JM, Holst JJ, et al. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. Eur J Endocrinol 2013; 169: 421-30.
60. Diabetes Prevention Program Research Group. HbA1c as a Predictor of Diabetes and as an Outcome in the Diabetes Prevention Program: A Randomized Clinical Trial. Diabetes Care 2015; 38(1): 51-8.
61. Xu Y, Wang L, He J. Prevalence and control of diabetes in chinese adults. JAMA 2013; 310(9): 948-59.
62. Monnier L, Lapinski H, Colette C. Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients: Variations with increasing levels of HbA1c. Diabetes Care 2003; 26(3): 881-5.
63. Riddle M, Umpierrez G, DiGenio A, et al. Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes. Diabetes Care 2011; 34(12): 2508-14.
64. Bianchi C, Miccoli R, Bonadonna RC, et al. Pathogenetic Mechanisms and Cardiovascular Risk: Differences between HbA1c and oral glucose tolerance test for the diagnosis of glucose tolerance. Diabetes Care 2012; 35(12): 2607-12.
65. Calanna S, Scicali R, Di Pino A, et al. Alpha-and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Acta Diabetol 2014; 1-9.
66. Noble D, Mathur R, Dent T, et al. Risk models and scores for type 2 diabetes: systematic review. BMJ 2011; 343: d7163.
67. Stern MP, Williams K, Haffner SM. Identification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test? Ann Intern Med 2002; 136(8): 575-81.
68. Abdul-Ghani MA, Lyssenko V, Tuomi T, et al. Fasting Versus Postload Plasma Glucose Concentration and the Risk for Future Type 2 Diabetes: Results from the Botnia Study. Diabetes Care 2009; 32(2): 281-6.
69. Abdul-Ghani MA, Williams K, DeFronzo RA, et al. What Is the Best Predictor of Future Type 2 Diabetes? Diabetes Care 2007; 30(6): 1544-8.
70. Bergman M, Chetrit A, Roth J, et al. Dysglycemia and long-term mortality: observations from the Israel study of glucose intolerance, obesity and hypertension. Diabetes Metab Res Rev 2014 Oct 28 [Epub ahead of print].
71. Tobe T, Kouchi M, Tanimura H, et al. Hyperglycemia after gastrectomy as a prediabetic state. Clinical study of 100 postgastrectomy patients. Arch Surg 1967; 94(6): 836-40.
72. Alyass A, Almgren P, Akerlund M, et al. Modelling of OGTT curve identifies 1 h plasma glucose level as a strong predictor of incident type 2 diabetes: results from two prospective cohorts. Diabetologia 2015; 58(1): 87-97.
73. Manco M, Panunzi S, Macfarlane DP, et al. One-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study. Diabetes Care 2010; 33(9): 2090-7.
74. Marini MA, Succurro E, Frontoni S, et al. Insulin sensitivity, betacell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels. Diabetes Care 2012; 35(4): 868-72.
75. Bianchi C, Miccoli R, Trombetta M, et al. Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired beta-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study. J Clin Endocrinol Metab 2013; 98(5): 2100-5.
76. Manco M, Miraglia Del GE, Spreghini MR, et al. 1-Hour plasma glucose in obese youth. Acta Diabetol 2012; 49(6): 435-43.
77. Su JB, Chen T, Xu F, et al. Glycemic variability in normal glucose regulation subjects with elevated 1-h postload plasma glucose levels. Endocrine 2014 Jun; 46(2): 241-8.
78. Kanauchi M, Kimura K, Kanauchi K, et al. Beta-cell function and insulin sensitivity contribute to the shape of plasma glucose curve during an oral glucose tolerance test in non-diabetic individuals. Int J Clin Pract 2005; 59(4): 427-32.
79. Abdul-Ghani MA, Lyssenko V, Tuomi T, et al. The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes. Diabetes Metab Res Rev 2010; 26(4): 280-6.
80. Tschritter O, Fritsche A, Shirkavand F, et al. Assessing the shape of the glucose curve during an oral glucose tolerance test. Diabetes Care 2003; 26(4): 1026-33.
81. Frøslie KF, Roislien J, Qvigstad E, et al. Shape information from glucose curves: functional data analysis compared with traditional summary measures. BMC Med Res Methodol 2013; 13: 6.
82. Perreault L, Pan Q, Mather KJ, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012; 379(9833): 2243-51.
83. Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005; 54(8): 2404-14.
84. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49(12): 2063-9.
85. Phillips LS, Ratner RE, Buse JB, et al. We can change the natural history of type 2 diabetes. Diabetes Care 2014; 37(10): 2668-76.
86. American Diabetes Association. Standards of Medical Care in Diabetes-2014. Diabetes Care 2014; 37(S1): S14-S80.
87. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369(2): 145-54.
88. Gregg EW, Chen H, Wagenknecht LE. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012; 308(23): 2489-96.
89. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393-403.
90. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18): 1343-50.
91. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20(4): 537-44.
92. Saito T, Watanabe M, Nishida J, et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med 2011; 171(15): 1352-60.
93. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374(9702): 1677-86.
94. Karstoft K, Winding K, Knudsen SH, et al. The effects of freeliving interval-walking training on glycemic control, body composition, and physical fitness in type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2013; 36(2): 228-36.
95. Church TS, Blair SN, Cocreham S. Effects of aerobic and resistance training on hemoglobin a1c levels in patients with type 2 diabetes: A randomized controlled trial. JAMA 2010; 304(20): 2253-62.
96. Sigal RJ, Kenny GP, Boulé NG, et al. Effects of Aerobic Training, Resistance Training, or Both on Glycemic Control in Type 2 DiabetesA Randomized Trial. Ann Intern Med 2007; 147(6): 357-69.
97. Balducci S, Zanuso S, Nicolucci A. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: A randomized controlled trial: the italian diabetes and exercise study (ides). Arch Intern Med 2010; 170(20): 1794-803.
98. Solomon TPJ, Sistrun SN, Krishnan RK, et al. Exercise and diet enhance fat oxidation and reduce insulin resistance in older obese adults. J Appl Physiol 2008; 104(5): 1313-9.
99. Goodpaster BH, Katsiaras A, Kelley DE. Enhanced Fat Oxidation Through Physical Activity Is Associated With Improvements in Insulin Sensitivity in Obesity. Diabetes 2003; 52(9): 2191-7.
100. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes-3-Year Outcomes. New Engl J Med 2014; 370(21): 2002-13.
101. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854-65.
102. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. Ned Engl J Med 2008; 358(24): 2545-59.
103. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35(6): 1364-79.
104. Bennett WL, Maruthur NM, Singh S, et al. Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations. Ann Intern Med 2011; 154(9): 602-13.
105. Bouchard C, Blair SN, Church TS, et al. Adverse Metabolic Response to Regular Exercise: Is It a Rare or Common Occurrence? PLoS ONE 2012; 7(5): e37887.
106. Boule NG, Weisnagel SJ, Lakka TA, et al. Effects of Exercise Training on Glucose Homeostasis: The HERITAGE Family Study. Diabetes Care 2005; 28(1): 108-14.
107. King NA, Hopkins M, Caudwell P, et al. Individual variability following 12 weeks of supervised exercise: identification and characterization of compensation for exercise-induced weight loss. Int J Obes 2007; 32(1): 177-84.
108. Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program. New Engl J Med 2006; 355(3): 241-50.
109. Lindholm ME, Marabita F, Gomez-Cabrero D, et al. An integrative analysis reveals coordinated reprogramming of the epigenome and the transcriptome in human skeletal muscle after training. Epigenetics 2014; 9(12): 1557-69.
110. Nielsen S, Scheele C, Yfanti C, et al. An integrative analysis reveals coordinated reprogramming of the epigenome and the transcriptome in human skeletal muscle after training. Epigenetics 2014 Muscle specific microRNAs are regulated by endurance exercise in human skeletal muscle. J Physiol 2010; 588(20): 4029-37.
111. Nielsen S, Åkerström T, Rinnov A, et al. The miRNA Plasma Signature in Response to Acute Aerobic Exercise and Endurance Training. PLoS ONE 2014; 9(2): e87308.
112. Hällsten K, Virtanen KA, Lönnqvist F, et al. Rosiglitazone but Not Metformin Enhances Insulin-and Exercise-Stimulated Skeletal Muscle Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes. Diabetes 2002; 51(12): 3479-85.
113. Boulé NG, Robert C, Bell GJ, et al. Metformin and Exercise in Type 2 Diabetes: Examining treatment modality interactions. Diabetes Care 2011; 34(7): 1469-74.
114. Malin SK, Gerber R, Chipkin SR, et al. Independent and Combined Effects of Exercise Training and Metformin on Insulin Sensitivity in Individuals With Prediabetes. Diabetes Care 2012; 35(1): 131-6.
115. Eshghi SRT, Bell GJ, Boulé NG. Effects of Aerobic Exercise with or without Metformin on Plasma Incretins in Type 2 Diabetes. Canadian J Diab 2013; 37(6): 375-80.
116. Massi-Benedetti M, Herz M, Pfeiffer C. The Effects of Acute Exercise on Metabolic Control in Type II Diabetic Patients Treated with Glimepiride or Glibenclamide. Horm Metab Res 1996; 28(09): 451-5.
117. Larsen JJ, Dela F, Madsbad S, et al. Interaction of sulfonylureas and exercise on glucose homeostasis in type 2 diabetic patients. Diabetes Care 1999; 22(10): 1647-54.
118. Larsen S, Stride N, Hey-Mogensen M, et al. Simvastatin Effects on Skeletal Muscle: Relation to Decreased Mitochondrial Function and Glucose Intolerance. J Am Coll Cardiol 2013; 61(1): 44-53.
119. Mikus CR, Boyle LJ, Borengasser SJ, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 2013; 62(8): 709-14.
120. Malin SK, Kirwan JP. Fasting hyperglycemia blunts the reversal of impaired glucose tolerance after exercise training in obese older adults. Diabet Obes Metab 2012; 14(9): 835-41.
121. Dela F, von-Linstow ME, Mikines KJ, et al. Physical training may enhance beta-cell function in type 2 diabetes. Am J Physiol Endocrinol Metab 2004; 287(5): E1024-E1031.
122. Krotkiewski M, Lönnroth P, Mandroukas K, et al. The effects of physical training on insulin secretion and effectiveness and on glucose metabolism in obesity and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1985; 28(12): 881-90.
123. Faria G, Preto J, Almeida AB, et al. Fasting glycemia: A good predictor of weight loss after RYGB. Surg Obes Rel Dis 2014; 10(3): 419-24.
124. English T, Malkani S, Kinney R, et al. Predicting Remission of Diabetes After RYGB Surgery Following Intensive Management to Optimize Preoperative Glucose Control. Obes Surg 2015; 25(1): 1-6.
125. Jurowich C, Thalheimer A, Hartmann D, et al. Improvement of Type 2 Diabetes Mellitus (T2DM) After Bariatric Surgery-Who Fails in the Early Postoperative Course? Obes Surg 2012; 22(10): 1521-6.
126. Dixon JB, Chuang LM, Chong K, et al. Predicting the Glycemic Response to Gastric Bypass Surgery in Patients With Type 2 Diabetes. Diabetes Care 2013; 36(1): 20-6.
127. Jones AG, Shields BM, Hyde CJ, et al. Identifying Good Responders to Glucose Lowering Therapy in Type 2 Diabetes: Implications for Stratified Medicine. PLoS ONE 2014; 9(10): e111235.
128. Pencek R, Blickensderfer A, Li Y, et al. Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations. Int J Clin Prac 2012; 66(11): 1021-32.
129. Rosenstock J, Shenouda SK, Bergenstal RM, et al. Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes. Diabetes Care 2012; 35(5): 955-8.
130. DeFronzo RA, Stonehouse AH, Han J, et al. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabetic Med 2010; 27(3): 309-17.
131. Esposito K, Chiodini P, Bellastella G, et al. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabet Obes Metab 2012; 14(3): 228-33.
132. Qiao Q, Pyorala K, Pyorala M, et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002; 23(16): 1267-75.
133. Færch K, Bergman B, Perreault L. Does insulin resistance drive the association between hyperglycemia and cardiovascular risk? PLoS ONE 2012; 7(6): e39260.
134. Barr EL, Boyko EJ, Zimmet PZ, et al. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia 2009; 52(3): 415-24.
135. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010; 55(13): 1310-7.
136. Kodama S, Saito K, Tanaka S, et al. Fasting and Post-Challenge Glucose as Quantitative Cardiovascular Risk Factors: A Meta-Analysis. J Atheroscler Thromb 2012; 19(4): 385-96.
137. Sarwar N, Aspelund T, Eiriksdottir G, et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med 2010; 7(5): e1000278.
138. Lind M, Tuomilehto J, Uusitupa M, et al. The association between HbA1c, fasting glucose, 1-hour glucose and 2-hour glucose during an oral glucose tolerance test and cardiovascular disease in individuals with elevated risk for diabetes. PLoS ONE 2014; 9(10): e109506.
139. Succurro E, Marini MA, Arturi F, et al. Elevated one-hour postload plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. Atherosclerosis 2009; 207(1): 245-9.
140. Succurro E, Arturi F, Lugara M, Grembiale A, Fiorentino TV, Caruso V, et al. One-hour postload plasma glucose levels are associated with kidney dysfunction. Clin J Am Soc Nephrol 2010 Nov; 5(11): 1922-7.
141. Selvin E, Steffes MW, Zhu H, et al. Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults. New Engl J Med 2010; 362(9): 800-11.
142. Paprott R, Schaffrath Rosario A, Busch MA, et al. Association Between Hemoglobin A1c and All-Cause Mortality: Results of the Mortality Follow-up of the German National Health Interview and Examination Survey 1998. Diabetes Care 2015; 38(2): 249-56.
143. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1cindependent risk factor for diabetic complications. JAMA 2006; 295(14): 1707-8.
144. McCoy RG, Van Houten HK, Ziegenfuss JY, et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012; 35(9): 1897-901.
145. Cobb J, Gall W, Adam KP, et al. A Novel Fasting Blood Test for Insulin Resistance and Prediabetes. J Diabetes Science Technol 2013; 7(1): 100-10.
146. Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol 2013; 9(9): 513-21.
147. Juraschek SP, Steffes MW, Selvin E. Associations of alternative markers of glycemia with hemoglobin A(1c) and fasting glucose. Clin Chem 2012; 58(12): 1648-55.
148. Nathan DM, McGee P, Steffes MW, et al. Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes 2014; 63(1): 282-90.
149. Meyer L, Chantrel F, Imhoff O, et al. Glycated albumin and continuous glucose monitoring to replace glycated haemoglobin in patients with diabetes treated with haemodialysis. Diabetic Med 2013; 30(11): 1388-9.
150. Yang C, Li H, Wang Z, Zhang W, et al. Glycated albumin is a potential diagnostic tool for diabetes mellitus. Clin Med 2012; 12(6): 568-71.